Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Merck News (NYSE:MRK)

Merck stock quote | Merck company information | Merck Stock Chart | Merck Stock News
DateTimeSource
Headline
03/27/20246:54AMIHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News
GameStop (NYSE:GME) – GameStop reported $1.79 billion in revenue for the fourth quarter, which is less than the $2.23 billion earned in the same quarter of the previous year. However, the company announced an adjusted earnings per share of 22 cents, compared to the previous year’s 16 cents per share. Shares... More...>>
03/26/20246:21PMBWFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
WINREVAIR is a breakthrough biologic for this rare, progressive disease WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced... More...>>
03/21/20246:45AMBWMerck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, did not meet its dual primary endpoints of overall survival (OS) and progression-free... More...>>
03/19/20249:00AMBWMerck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Results from multiple Phase 3 trials of V116 and a real-world evidence study of pneumococcal serotypes presented at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults Merck (NYSE: MRK... More...>>
03/15/20244:23PMPRNUSFarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform PR Newswire HOD HASHARON, Israel, March 15, 2024 Cutting edge & AI solution for continuous and precise monitoring of individual swine weight HOD HASHARON, Israel, March 15, 2024 /PRNewswire/ -- FarmSee, a pioneer in camera-based... More...>>
03/15/20246:45AMBWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
KEYTRUDA plus CRT is the first immunotherapy-based regimen to demonstrate a statistically significant improvement in OS in these patients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA... More...>>
03/13/20243:00AMBWMerck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine... More...>>
03/11/20248:15AMBWMerck Completes Acquisition of Harpoon Therapeutics, Inc.
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics... More...>>
03/06/202410:25AMBWGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
– Week 24 Results Support Continued Development as a Potential Long-Acting Oral Combination Treatment Option in Virologically Suppressed People with HIV – – Novel Investigational Combination Regimen has the Potential to be the First Oral Weekly HIV Treatment, Helping to Address Unmet Needs – Gilead Sciences, Inc... More...>>
03/05/20249:03AMIHMARKETNEWSFutures Pointing To Continued Weakness On Wall Street
The major U.S. index futures are currently pointing to a lower open on Tuesday, with stocks likely to see further downside following the modest pullback seen on Monday. Traders may continue to cash in on recent strength in the markets, which lifted the S&P 500 and the Nasdaq to record closing highs last Friday. Uncertainty... More...>>
03/05/20246:45AMBWMerck to Participate in the Barclays 26th Annual Global Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., is scheduled to participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024, at 3:05 p.m. EDT. Investors, analysts, members... More...>>
03/04/20246:45AMBWMerck to Participate in the Leerink Partners Global Biopharma Conference 2024
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024... More...>>
02/27/20246:45AMBWMerck to Participate in the TD Cowen 44th Annual Health Care Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET. Investors, analysts, members... More...>>
02/23/20246:20AMBWMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial First opinion to be granted for an anti-PD-1/L1 therapy in resectable non-small cell lung cancer (NSCLC) based on positive overall survival results Merck (NYSE: MRK), known as MSD outside of the United... More...>>
02/20/20246:45AMBWFDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
Acceptance based on results from the pivotal Phase 3 NRG-GY018 trial Results showed KEYTRUDA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in these patients, regardless of mismatch repair status Merck (NYSE: MRK), known... More...>>
02/12/20247:05AMPRNCASanté Canada approuve KEYTRUDA®, en association avec le trastuzumab et une chimiothérapie, comme traitement de première intention pour les patients atteints d'un adénocarcinome gastrique ou de la jonction œsophago-gastrique non résécable localement
Santé Canada approuve KEYTRUDA®, en association avec le trastuzumab et une chimiothérapie, comme traitement de première intention pour les patients atteints d'un adénocarcinome gastrique ou de la jonction œsophago-gastrique non résécable localement avancé ou métastatique... More...>>
02/12/20247:05AMPRNCAHealth Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumours expr
Health Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumours express PD-L1 (CPS ≥ 1) Canada NewsWire KIRKLAND, QC, Feb... More...>>
02/08/20247:00AMPRNCAMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE
MERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE Canada NewsWire KIRKLAND, QC, Feb. 8, 2024 KIRKLAND, QC, Feb. 8, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, has entered into... More...>>
02/08/20247:00AMPRNCAMERCK CANADA ANNONCE UNE COLLABORATION AVEC L'INSTITUT VECTOR POUR FAIRE AVANCER SES CAPACITÉS D'INTELLIGENCE ARTIFICIELLE ET FAVORISER L'INNOVATION DANS LE DOMAINE DES SOINS DE SANTÉ
MERCK CANADA ANNONCE UNE COLLABORATION AVEC L'INSTITUT VECTOR POUR FAIRE AVANCER SES CAPACITÉS D'INTELLIGENCE ARTIFICIELLE ET FAVORISER L'INNOVATION DANS LE DOMAINE DES SOINS DE SANTÉ Canada NewsWire KIRKLAND, QC, le 8 févr. 2024 KIRKLAND, QC, le 8 févr. 2024 /CNW/ - Merck (NYSE: MRK), connue... More...>>
02/05/20246:33AMBWMerck Animal Health to Acquire Elanco’s Aqua Business
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries Complements Merck Animal Health’s broad portfolio of veterinary pharmaceuticals, vaccines and technology solutions Merck Animal Health... More...>>